Product Information
ROFLUMILAST 250 MCG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $1.9813 per EA under NDC 68382062431. Its NADAC has been published 130 times since Apr 10, 2024.
FDA first approved this application on Feb 10, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 ug/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382062431
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ROFLUMILASTApproval Type
Generic (ANDA)
FDA Application
ANDA208303FDA Approved
2/10/2022
TE Code
AB
On Market Since
5/18/2023
Pharmacological Classes
Price Statistics
The NADAC for ROFLUMILAST 250 MCG TABLET has been published 130 times since Apr 10, 2024, and over the history we have for it it has declined 34.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9813 per EA |
|---|---|
| All-time high | $3.0148 (Apr 10, 2024) |
| All-time low | $1.5913 (Jul 17, 2024) |
| 52-week high | $2.3559 |
| 52-week low | $1.9069 |
| Median price | $2.3296 |
| Average price | $2.2806 |
| Largest weekly change | +63.4% (Aug 21, 2024) |
| Weeks tracked | 130 |
| Tracking since | Apr 10, 2024 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Roflumilast market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ROFLUMILAST 250 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROFLUMILAST 250 MCG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $1.9813 per EA (NDC 68382062431), effective Sep 30, 2026.
How has the price of ROFLUMILAST 250 MCG TABLET changed over time?
Over the history we have for it, the NADAC for ROFLUMILAST 250 MCG TABLET has declined 34.3%. It has been tracked across 130 weekly CMS publications since Apr 10, 2024.
What are the highest and lowest recorded NADAC prices for ROFLUMILAST 250 MCG TABLET?
Since Apr 10, 2024, the NADAC for ROFLUMILAST 250 MCG TABLET has ranged from a low of $1.5913 (Jul 17, 2024) to a high of $3.0148 (Apr 10, 2024), with a median of $2.3296 per EA.
Are there cheaper alternatives to ROFLUMILAST 250 MCG TABLET?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ROFLUMILAST 250 MCG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ROFLUMILAST 250 MCG TABLET?
ROFLUMILAST 250 MCG TABLET (NDC 68382062431) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.